JP6518199B6 - Ｍｉｃａおよびｍｉｃｂタンパク質に対する抗体 - Google Patents

Ｍｉｃａおよびｍｉｃｂタンパク質に対する抗体 Download PDF

Info

Publication number
JP6518199B6
JP6518199B6 JP2015562400A JP2015562400A JP6518199B6 JP 6518199 B6 JP6518199 B6 JP 6518199B6 JP 2015562400 A JP2015562400 A JP 2015562400A JP 2015562400 A JP2015562400 A JP 2015562400A JP 6518199 B6 JP6518199 B6 JP 6518199B6
Authority
JP
Japan
Prior art keywords
seq
amino acid
antibody
mica
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015562400A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016512223A5 (enExample
JP2016512223A (ja
JP6518199B2 (ja
Inventor
チェニー，イアン・ウェイン
Original Assignee
ノヴェロジックス・バイオテクノロジー，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノヴェロジックス・バイオテクノロジー，インコーポレーテッド filed Critical ノヴェロジックス・バイオテクノロジー，インコーポレーテッド
Publication of JP2016512223A publication Critical patent/JP2016512223A/ja
Publication of JP2016512223A5 publication Critical patent/JP2016512223A5/ja
Application granted granted Critical
Publication of JP6518199B2 publication Critical patent/JP6518199B2/ja
Publication of JP6518199B6 publication Critical patent/JP6518199B6/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2015562400A 2013-03-15 2014-03-15 Ｍｉｃａおよびｍｉｃｂタンパク質に対する抗体 Expired - Fee Related JP6518199B6 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361801329P 2013-03-15 2013-03-15
US61/801,329 2013-03-15
US201461940372P 2014-02-15 2014-02-15
US61/940,372 2014-02-15
PCT/IB2014/001157 WO2014140904A2 (en) 2013-03-15 2014-03-15 Antibodies to mica and micb proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019080239A Division JP2019194180A (ja) 2013-03-15 2019-04-19 Ｍｉｃａおよびｍｉｃｂタンパク質に対する抗体

Publications (4)

Publication Number Publication Date
JP2016512223A JP2016512223A (ja) 2016-04-25
JP2016512223A5 JP2016512223A5 (enExample) 2017-04-20
JP6518199B2 JP6518199B2 (ja) 2019-05-22
JP6518199B6 true JP6518199B6 (ja) 2019-06-12

Family

ID=51538216

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015562400A Expired - Fee Related JP6518199B6 (ja) 2013-03-15 2014-03-15 Ｍｉｃａおよびｍｉｃｂタンパク質に対する抗体
JP2019080239A Pending JP2019194180A (ja) 2013-03-15 2019-04-19 Ｍｉｃａおよびｍｉｃｂタンパク質に対する抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019080239A Pending JP2019194180A (ja) 2013-03-15 2019-04-19 Ｍｉｃａおよびｍｉｃｂタンパク質に対する抗体

Country Status (6)

Country Link
US (2) US10851148B2 (enExample)
EP (1) EP2970490A4 (enExample)
JP (2) JP6518199B6 (enExample)
AU (1) AU2014229476B2 (enExample)
CA (1) CA2906356A1 (enExample)
WO (1) WO2014140904A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009114085A2 (en) 2008-03-03 2009-09-17 The University Of Miami Allogeneic cancer cell-based immunotherapy
EP3116903A2 (en) * 2014-03-14 2017-01-18 Dana-Farber Cancer Institute, Inc. Vaccine compositions and methods for restoring nkg2d pathway function against cancers
WO2015179627A1 (en) * 2014-05-21 2015-11-26 Dana-Farber Cancer Institute, Inc. Methods for treating cancer with anti bip or anti mica antibodies
AU2015292744C1 (en) 2014-07-21 2021-01-21 Novartis Ag Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
US10046047B2 (en) 2015-02-06 2018-08-14 Heat Biologics, Inc. Vector co-expressing vaccine and costimulatory molecules
MX2018006785A (es) * 2015-12-04 2018-11-09 Dana Farber Cancer Inst Inc Vacunacion con el dominio alfa 3 de mica/b para el tratamiento del cancer.
US11666649B2 (en) 2016-10-11 2023-06-06 University Of Miami Vectors and vaccine cells for immunity against Zika virus
WO2018073648A1 (en) 2016-10-19 2018-04-26 Novelogics Biotechnology, Inc. Antibodies to mica and micb proteins
CN107964041B (zh) * 2016-10-20 2023-08-01 中国科学院广州生物医药与健康研究院 高稳定性和高亲和力的dmic及其制法
EP3532091A2 (en) * 2016-10-29 2019-09-04 H. Hoffnabb-La Roche Ag Anti-mic antibidies and methods of use
CN108204958A (zh) * 2016-12-19 2018-06-26 伊缪泰普有限公司 结合测定
WO2018141959A1 (en) 2017-02-06 2018-08-09 Innate Pharma Immunomodulatory antibody drug conjugates binding to a human mica polypeptide
WO2018187260A1 (en) 2017-04-04 2018-10-11 Heat Biologics, Inc. Intratumoral vaccination
MX2020007880A (es) * 2018-01-25 2021-05-14 Cullinan Mica Corp Anticuerpos de mica/b y metodos de uso.
JP7351845B2 (ja) 2018-03-23 2023-09-27 ブリストル－マイヤーズ スクイブ カンパニー Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用
IL279367B2 (en) 2018-06-13 2026-05-01 Novartis Ag BCMA chimeric antigen receptors and their uses
KR102832008B1 (ko) * 2018-07-31 2025-07-10 컬리난 미카 코퍼레이션 Mica/b 유출을 차단하는 항-mica/b 항체 및 사용 방법
WO2020035345A1 (en) 2018-08-14 2020-02-20 Innate Pharma Treatment of colorectal cancer by a combination of an anti-mica antibody and an anti-nkg2a antibody
BR112021012066A2 (pt) 2018-12-21 2021-11-03 Onxeo Novas moléculas de ácido nucleico conjugadas e seus usos
CN113811329B (zh) * 2019-04-19 2025-10-14 天科雅生物科技有限公司 抗pd-1抗体和其用途
EP4017876A4 (en) * 2019-08-23 2023-09-06 Northwestern University MATERIALS AND METHODS FOR ACTIVATING ANTIGEN-SPECIFIC T CELL RESPONSES
AR122644A1 (es) 2020-06-19 2022-09-28 Onxeo Nuevas moléculas de ácido nucleico conjugado y sus usos
CN116547301A (zh) * 2020-08-10 2023-08-04 先天制药公司 使用抗体进行的细胞表面mica和micb检测
CN112574311B (zh) * 2020-12-14 2022-03-25 广州康盛生物科技股份有限公司 双mic结合活性的抗体及其应用
US20240216554A1 (en) * 2021-05-04 2024-07-04 Actinium Pharmaceuticals, Inc. Radioimmunoconjugates directed to nkg2d ligands for the treatment of cancer
CA3240558A1 (en) 2021-12-16 2023-06-22 Valerio Therapeutics New conjugated nucleic acid molecules and their uses
CN119998318A (zh) * 2022-04-08 2025-05-13 D2M生物治疗有限公司 抗mica/b抗体及其用途
KR102783449B1 (ko) * 2022-06-15 2025-03-19 주식회사 셀리드 자연 살해 ｔ 세포의 리간드와 암 항원을 적재한 자연 살해 세포를 포함하는 백신

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0937258A2 (en) 1996-10-29 1999-08-25 Fred Hutchinson Cancer Research Center, Inc. Cell stress regulated human mhc class i gene
JP2005523681A (ja) 2001-10-04 2005-08-11 イミュネックス・コーポレーション Ｕｌ１６結合タンパク質４
CA2483343A1 (en) * 2002-04-22 2003-10-30 Fred Hutchinson Cancer Research Center Soluble mic polypeptides as markers for diagnosis, prognosis and treatment of cancer and autoimmune diseases or conditions
US7666417B2 (en) 2003-04-22 2010-02-23 Fred Hutchinson Cancer Research Center Methods and compositions for treating autoimmune diseases or conditions
AU2005240082B2 (en) 2004-04-30 2009-07-23 Innatus Corporation Method and system to remove soluble TNFR1,TNFR2, and IL2 in patients
DE102004042894A1 (de) 2004-08-30 2006-03-02 Eberhard-Karls-Universität Tübingen Verwendung von Blockern der NKG2D-Rezeptor-/NKG2D-Liganden-Interaktion bei Autoimmunerkrankungen
US20100111973A1 (en) 2006-09-22 2010-05-06 Glenn Dranoff Methods for treating mica-related disorders
WO2008131406A2 (en) 2007-04-23 2008-10-30 Fred Hutchinson Cancer Research Center NEGATIVE IMMUNOMODULATION OF IMMUNE RESPONSES BY ERp5
US8182809B1 (en) * 2008-09-08 2012-05-22 University Of Washington Methods for treating cancer by inhibiting MIC shedding
ES2550384T3 (es) 2008-12-18 2015-11-06 Dana-Farber Cancer Institute, Inc. NKG2D-Fc para la inmunoterapia
US8796420B2 (en) 2009-12-31 2014-08-05 Avidbiotics Corp. Non-natural MIC proteins
TWI408370B (zh) 2011-05-19 2013-09-11 長庚大學 胰臟癌之血清生物檢測標誌及其應用
US8753640B2 (en) * 2011-05-31 2014-06-17 University Of Washington Through Its Center For Commercialization MIC-binding antibodies and methods of use thereof
DK2760471T3 (en) 2011-09-30 2017-05-08 Dana Farber Cancer Inst Inc THERAPEUTIC PEPTIDES
JP6405242B2 (ja) 2012-02-07 2018-10-17 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． Ｍｉｃａ結合剤
EP2626994B1 (en) 2012-02-08 2019-04-03 GE Oil & Gas UK Limited Supplying electrical power to subsea equipment
WO2014140884A2 (en) 2013-03-15 2014-09-18 Novelogics Biotechnology, Inc. Methods and devices for removal of immunosuppressive ligands

Also Published As

Publication number Publication date
EP2970490A4 (en) 2017-04-26
WO2014140904A2 (en) 2014-09-18
US20210040173A1 (en) 2021-02-11
AU2014229476B2 (en) 2019-07-11
JP2016512223A (ja) 2016-04-25
US20160046689A1 (en) 2016-02-18
US10851148B2 (en) 2020-12-01
EP2970490A2 (en) 2016-01-20
AU2014229476A1 (en) 2015-10-01
JP6518199B2 (ja) 2019-05-22
JP2019194180A (ja) 2019-11-07
CA2906356A1 (en) 2014-09-18
WO2014140904A3 (en) 2014-12-31

Similar Documents

Publication Publication Date Title
JP6518199B2 (ja) Ｍｉｃａおよびｍｉｃｂタンパク質に対する抗体
US11066471B2 (en) Antibodies to MICA and MICB proteins
JP6799101B2 (ja) クローディンを発現するガン疾患を処置するための剤
JP7080213B2 (ja) 新規抗ｐｄ－ｌ１抗体
US20250289880A1 (en) Use of anti-fam19a5 antibodies for treating cancers
TW202123926A (zh) 使用her3抗原結合分子的癌症之治療及預防
KR20210015902A (ko) Psma 결합제 및 이의 용도
US12552873B2 (en) Anti-PSGL-1 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
TW202003568A (zh) Vista抗原結合分子
CN104024276A (zh) Lsr抗体及其用于癌症治疗的用途
TW201942136A (zh) Her3抗原結合分子
JP7716623B2 (ja) 排出ポンプ－癌抗原マルチ特異性抗体ならびにそれに関する組成物、試薬、キットおよび方法
UA119673C2 (uk) Біспецифічне fc-діатіло, здатне імуноспецифічно зв'язуватися з епітопом pd-1 і з епітопом lag-3, та його застосування
ES2290072T3 (es) Anticuerpos frente a la proteina semp1, metodos para su produccion y usos de los mismos.
TW200916482A (en) Bone morphogenetic protein (BMP)-binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and use of same
AU2018394255A1 (en) Bispecific antibody construct directed to MUC17 and CD3
JP7858550B2 (ja) 重症急性呼吸器症候群コロナウイルス２（ｓａｒｓ－ｃｏｖ－２）ポリペプチドおよびワクチン目的でのその使用
JP2019526528A (ja) 抗ｔｎｆｒｓｆ２５抗体
US20220251233A1 (en) Anti-cd53 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
JP2023530997A (ja) Ｂｓｔ２ロングアイソフォームを標的化する抗ｂｓｔ２抗体
RU2811431C2 (ru) Антитело против клаудина 18a2 и его применение
NZ751584B2 (en) Antibodies to mica and micb proteins
NZ751584A (en) Antibodies to mica and micb proteins
HK1260737B (en) Novel anti-pd-l1 antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170313

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170313

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180410

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180709

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180907

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190322

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190419

R150 Certificate of patent or registration of utility model

Ref document number: 6518199

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R154 Certificate of patent or utility model (reissue)

Free format text: JAPANESE INTERMEDIATE CODE: R154

R150 Certificate of patent or registration of utility model

Ref document number: 6518199

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees